CurrentBlue Cross Blue Shield - Rhode IslandPolicy N/A

Medical Coverage Policy Prolotherapy

Defines Blue Cross Blue Shield Rhode Island medical coverage position for prolotherapy (proliferant injections) for musculoskeletal indications, including statement of not medically necessary for commercial and Medicare Advantage plans and coding guidance.

Policy Summary

PayerBlue Cross Blue Shield - Rhode Island

PolicyMedical Coverage Policy Prolotherapy

Policy CodePolicy N/A

Change TypeReaffirmation

Effective DateAug 2, 2007

Next Review Date

Key ActionVerify member-specific benefits/coverage in the appropriate Benefit Booklet, Evidence of Coverage, or Subscriber Agreement as benefits may vary between groups and contracts.

SourceLink

POLICY UPDATE CHANGES

Policy last reviewed 11/20/2024; policy statement maintains that prolotherapy is not covered / not medically necessary for musculoskeletal conditions due to insufficient evidence.

1HCPCS code listed as not covered

Commercial & Medicare AdvantagePlans affected

Insufficient evidenceCoverage rationale

Coverage Summary

Prolotherapy (also called proliferant injection, prolo, joint sclerotherapy, regenerative injection therapy) involves injecting agents intended to promote tissue repair by inducing local inflammation or releasing growth factors. The payer position is that prolotherapy is not covered / not medically necessary for musculoskeletal conditions for both Commercial and Medicare Advantage plans. This determination is based on insufficient evidence from small, inconsistent trials and reviews that do not demonstrate a clear improvement in net health outcomes for pain and related functional measures.

Key policy facts

Coverage stanceProlotherapy is not covered / not medically necessary for musculoskeletal conditions (not covered for Medicare Advantage; not medically necessary for Commercial Products).

Plans affectedCommercial & Medicare Advantage

Effective date2007-08-02

Last review2024-11-20

Policy scopeDefines BCBSRI medical coverage position for prolotherapy for musculoskeletal indications; states prolotherapy is not medically necessary for commercial and Medicare Advantage plans and provides coding guidance.

Policy Statement / Coverage Determination

Prolotherapy coverage determination:

ALL of the following

Prolotherapy is not covered as a treatment of musculoskeletal conditions because the evidence is insufficient to determine that the technology results in an improvement in the net health outcome (pain).
For Commercial Products: Prolotherapy is not medically necessary as treatment of musculoskeletal conditions as the evidence is insufficient to determine improvement in net health outcome (pain).
For Medicare Advantage Plans: The listed code(s) for prolotherapy are not covered.

Not Covered / Coding Guidance

Not covered / Not medically necessary codeHCPCSNot Covered

M0076

Prolotherapy

For Medicare Advantage, note that the Centers for Medicare & Medicaid Services has a National Coverage Determination: NCD 150.7 — PROLOTHERAPY, Joint Sclerotherapy, and Ligamentous Injections with Sclerosing Agents, which is referenced in the policy determination for prolotherapy.

Provider Actions

Documentation Required

Benefit verification

Verify member-specific benefits/coverage in the appropriate Benefit Booklet, Evidence of Coverage, or Subscriber Agreement as benefits may vary between groups and contracts.

Billing Rule

Claims for non-covered service

Do not bill members for services determined to be not medically necessary unless the member has been informed and has agreed in writing in advance to continue treatment at their own expense, per participation agreement.

Background and Evidence

Prolotherapy uses agents such as hypertonic dextrose, glycerin, phenol, polidocanol, sodium morrhuate, zinc sulfate, and others, often combined with a local anesthetic, to provoke local irritation, cell lysis, or release of growth factors with the intent of promoting tissue repair. Treatments typically involve multiple injections per session across a series of sessions; the exact mechanism is not well understood but is thought to involve induction of a local inflammatory response or enhancement of circulating growth factor effects.

The evidence base consists primarily of small randomized trials and systematic reviews with inconsistent results across musculoskeletal indications. While the strongest body of research evaluates prolotherapy for osteoarthritis, the clinical significance of observed effects is uncertain. Overall, available trials and reviews are insufficient to conclude that prolotherapy produces a net health benefit for pain, function, or quality of life in musculoskeletal conditions.

Definition

ProlotherapyProcedure intended for healing and strengthening ligaments and tendons by injecting an agent that induces inflammation and stimulates endogenous repair mechanisms; also called proliferant injection, prolo, joint sclerotherapy, regenerative injection therapy.

NCD Number	Name	Effective Year	Type
150.7	PROLOTHERAPY, Joint Sclerotherapy, and Ligamentous Injections with Sclerosing Agents	1999	NCD